Hypersensitivity

BOSTON — Physicians should consider delayed hypersensitivity reactions such as serum sickness when patients experience symptoms during biologic treatment, according to a poster presented at the CHEST Annual Meeting.

Adults with asthma who also had laryngeal hypersensitivity had a greater symptom burden during the 2019 to 2020 landscape fires in Australia, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

SAN ANTONIO — Patients with a history of delayed hypersensitivity to iodinated contrast media exhibited a broad cross-reactivity pattern, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

NEW ORLEANS – Borderline personality disorder can be effectively treated by using the good psychiatric management approach, Lois W. Choi-Kain, MD, said here at the American Psychiatric Association annual meeting.

A 3-year old boy presented to the ED for evaluation of an itchy rash. One week before presentation, he had complained of ear pain and was prescribed amoxicillin by his pediatrician for otitis media. A week later, he developed rhinorrhea, cough and a pruritic rash. The rash started on his hands and feet, then spread to his trunk and extremities. Some lesions seemed to disappear within a few hours. His hands and feet became swollen, and he developed pain with ambulation, prompting the ED visit for evaluation.

Both allopurinol and febuxostat carry similar, significant increased risks for hypersensitivity reactions compared with colchicine, according to data published in Annals of the Rheumatic Diseases.

What is a GI psychologist? Although those of us who identify as GI psychologists often find ourselves explaining what that means to our colleagues, it is exactly what it sounds like: we are psychologists specializing in working with people who have GI conditions. We alternate between academic descriptors “psychogastroenterology” and “gastropsych,” representing the natural marriage of the worlds of psychology and gastroenterology.

Inclisiran, an investigational cholesterol-lowering therapy, reduced LDL in high-risk patients with atherosclerotic CVD and in those with heterozygous familial hypercholesterolemia, or FH, according to data from the ORION-10 and ORION-9 trials, respectively.